Swedish biotech startup Re:meat has adopted a new name, Curve, as the company shifts from a cultivated meat focus to a wider protein manufacturing platform intended for large-volume industrial use. The rebrand follows a year of funding activity and facility development as the team positions its technology for multiple sectors that depend on functional proteins.
Curve’s work centers on modular bioreactor systems designed to bridge the gap between basic food-grade fermenters and high-cost pharmaceutical equipment. The company says this approach is intended to support commercially viable output for applications in food, health, materials, cosmetics and other protein-driven categories.
“Tools built for this century”
Co-founder and CEO Jacob Schaldemose Peterson stated, “Scaling biotech is the next industrial revolution. But it demands tools built for this century, not the last. With Curve, our ambition is to unlock scalable biomanufacturing at cost points that finally make industrial deployment possible.”
The BIOBRIC platform sits at the center of Curve’s offering. According to the company, the system is engineered to reduce capital expenditure by up to seventy percent while accelerating process development for both precision fermentation and cultivated meat. Curve says it collaborates with fermentation and advanced biotech companies on strain and media optimization before licensing the validated systems to producers.
Earlier this year, the former Re:meat team closed a one-million-euro funding round led by 8+ Ventures. The financing was used to support what the company described as Scandinavia’s first “re:meatery,” a facility modeled on a brewery but dedicated to cultivated meat. Later, a partnership with Biotech Heights at the Lund University Prepilot Plant advanced that plan.
Positioning beyond a single sector
With the rebrand now formalized, Curve positions its technology as relevant far beyond alternative protein startups. The company states that demand for affordable protein ingredients is increasing across nutrition, healthcare, materials and animal feed, yet existing infrastructure was not designed for these markets. Curve’s leadership argues that industrial-scale biomanufacturing will require new equipment architectures supported by real-time data handling and integrated software.
Investor and board member Torbjörn Sahlén said, “Cost-efficient cultivated meat production has always been the ambition for Re:meat. However, experience shows that if we focus exclusively on that, we are not maximising our ability to scale and leave significant potential untapped. This shift, and consequently the name change to Curve, reflects this strategic opportunity.”
